ClinicalTrials.gg
RecruitingNCT07430761Updated Feb 24, 2026

ET Stigma Response to Tremor Suppression

An observational study in Action Tremor and Stigma, Social, sponsored by University of Texas Southwestern Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-24.

Sponsored by University of Texas Southwestern Medical Center · Observational

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.
Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
220
Ages
18 Years and older
Sex
All
01

Study summary

Essential Tremor (ET) is prevalent, affecting approximately 3% of the adult population. Involuntary shaking of the hands during action is a prominent feature, interfering with feeding and writing and other manual tasks. The involuntary movement is visible to observers, some of whom misinterpret the shakiness as manifestation of anxiety or instability, while some other observers attribute it to alcohol or drug use. The psychological effects of resulting stigma on quality of life for people with ET can rival the physical difficulties caused by the condition.

For this study, we propose to measure 1 year after effective tremor suppression following thalamotomy with high intensity focused ultrasound changes from baseline in psychological distress and social dysfunction related to ET stigma, and to correlate change from baseline with improvement in functional status related to tremor and in objective measures of tremor severity. We hope to discover that ET stigma is largely reversible when tremor is effectively treated, and we aim to learn what degree of tremor suppression correlates with substantial psychological relief. We will also determine if ET stigma is predominantly helped by unilateral dominant-hand treatment, or if the second side treatment is necessary to accomplish most benefit.

Read the detailed description

Study procedures:

Subjects will complete the following three surveys on two occasions i.e. at baseline, hours or days before thalamotomy, and again 12 months after the procedure (with a window of 11 to 18 months). Completing the three surveys takes approximately 5 minutes.

  1. The ET-stigma distress scale which has 11 items each with 5 response options ranging from "strongly disagree" to "strongly agree"
  2. the ET stigma dysfunction scale which has 5 items each with 3 response options ranging from "not at all or rarely" to "frequently"
  3. the Tremor Disability Scale-Revised with 20 items each with 4 response options ranging from "no difficulty" to "cannot perform the task".
02

Conditions studied

  • Action Tremor
  • Stigma, Social

Keywords

  • Essential tremor
  • stigma
  • thalamotomy
  • high intensity focused ultrasound
03

In context

Tremor

158 studies on the registry are indexed under Tremor; 44 are open to participants now.

This study's planned enrollment of 220 is above the median of 74 across 45 observational studies indexed under Tremor.

Browse Tremor studies →

Lead sponsor

University of Texas Southwestern Medical Center is the lead sponsor of 1,010 studies on the registry; 199 are open to participants now.

Of its 139 completed or terminated interventional studies of FDA-regulated products, 105 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients who are scheduled to undergo stereotactic thalamotomy guided by four-tract tractography at the University of Texas Southwestern Medical Center for the treatment of Essential Tremor (ET). As is standard of practice, the diagnosis of ET and the judgment that this procedure is medically necessary will have been made by a movement disorder specialist. Once the procedure is scheduled, patients are invited to participate in this observational prospective study of effects on ET stigma.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • People with ET as diagnosed by a movement disorder neurologist
  • Tremor of sufficient severity and impact on quality of life so as to justify a lesional brain procedure
  • Competent to consent to undergoing high intensity focused ultrasound thalamotomy targeted by 4-tract tractography
  • Provide verbal to this study of ET stigma

Exclusion criteria

Exclusion Criteria:

  • Patient declines to participate in this observational study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
220 participants (estimated)
Patient registry
No

Groups and cohorts

  • ET for thalamotomy

    Patients with diagnosis of problematic essential tremor refractory to pharmacologic treatment who are to undergo stereotactic thalamotomy with high intensity focused ultrasound.

    Procedure: stereotactic thalamotomy with focused ultrasound

Interventions

  • Procedurestereotactic thalamotomy with focused ultrasound

    stereotactic thalamotomy with high intensity focused ultrasound, guided by four-tract tractography

06

What researchers measure

Primary outcomes

  1. ET stigma psychological distress

    Psychological distress related to other people's reaction to their tremor.

    Time frame: change from baseline before thalamotomy to 12 months after thalamotomy

  2. ET stigma social dysfunction

    Social avoidance and maladaptive behaviors related to other people's reaction to tremor.

    Time frame: change from baseline before thalamotomy to 12 months after thalamotomy

Other outcomes

  1. Tremor Disability Scale - Revised

    self-assessed impact of tremor on skilled manual function

    Time frame: change from baseline before thalamotomy to 12 months after thalamotomy

  2. TETRAS - Performance Scale

    tremor severity measured objectively

    Time frame: change from baseline before thalamotomy to 12 months after thalamotomy

07

Study locations

1 of 1 sites recruiting
  • University of Texas Soouthwestern Medical Center
    Dallas, Texas 75390, United States
    Recruiting
    • Padraig E O'Suilleabhain, MD · Contact214-648-8737
08

References and documents

Individual participant data

Plan to share: No — deidentified data will be shared on request with researchers employed by accredited third level institutions.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2025 (actual). Primary completion is estimated for May 2027, 28 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2026
First posted
Feb 24, 2026
StartActual
Jan 1, 2025
Primary completionEst.
May 30, 2027
CompletionEst.
Aug 30, 2027
Last update
Feb 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07430761
Responsible party
Padraig O'Suilleabhain (Professor, University of Texas Southwestern Medical Center) — Principal investigator
First posted
Feb 24, 2026
Start date
Jan 1, 2025
Primary completion
May 30, 2027 (estimated)
Completion
Aug 30, 2027 (estimated)
Last update
Feb 24, 2026

Study contacts

Padraig E O'Suilleabhain, MD
Contact
padraig.osuilleabhain@utsouthwestern.edu
2146482943
Padraig E O'Suilleabhain
Contact
2146482943
Padraig E O'Suilleabhain, MD
principal investigator · University of Texas Southwestern Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion